BUZZ-Australia's LTR Pharma hits record high on partnership for nasal spray

Reuters08-13

** Shares of LTR Pharma soar as much as 29.5% to a record high of A$1.250

** Biopharmaceutical co signs co-development agreement with Aptar Pharma for SPONTAN nasal spray for global markets

** Primary goal is commercialisation of SPONTAN in the United States and other key markets - co

** Says partnership with Aptar Pharma will be beneficial in obtaining U.S. Food and Drug Administration (FDA) approval for SPONTAN

** Stock posts its biggest intraday pct gain since June 7

** About 2.3 mln shares change hands, compared with the 30-day average volume of 600,999

** Stock up 179.7% this year, as of last close

(Reporting by Rajasik Mukherjee in Bengaluru)

((Rajasik.Mukherjee@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment